Your browser is no longer supported. Please, upgrade your browser.
Aerie Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.61 Insider Own0.30% Shs Outstand46.20M Perf Week-22.19%
Market Cap582.95M Forward P/E- EPS next Y-1.65 Insider Trans0.00% Shs Float46.09M Perf Month-10.33%
Income-166.40M PEG- EPS next Q-0.62 Inst Own- Short Float10.89% Perf Quarter-21.62%
Sales94.90M P/S6.14 EPS this Y9.20% Inst Trans-2.02% Short Ratio9.52 Perf Half Y-34.28%
Book/sh-0.86 P/B- EPS next Y36.50% ROA-44.80% Target Price- Perf Year9.75%
Cash/sh4.18 P/C3.10 EPS next 5Y- ROE- 52W Range9.01 - 21.30 Perf YTD-4.22%
Dividend- P/FCF- EPS past 5Y-6.70% ROI-68.70% 52W High-39.25% Beta0.88
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin73.90% 52W Low43.62% ATR1.02
Employees365 Current Ratio2.70 Sales Q/Q51.10% Oper. Margin- RSI (14)37.61 Volatility10.37% 6.10%
OptionableYes Debt/Eq- EPS Q/Q20.30% Profit Margin- Rel Volume2.57 Prev Close12.34
ShortableYes LT Debt/Eq- EarningsAug 04 AMC Payout- Avg Volume527.43K Price12.94
Recom2.00 SMA20-12.61% SMA50-14.17% SMA200-20.11% Volume1,356,597 Change4.86%
Oct-19-20Downgrade BofA Securities Neutral → Underperform $14 → $9
Sep-08-20Resumed Guggenheim Buy $20
Aug-07-20Reiterated Needham Buy $32 → $26
Jun-01-20Resumed Oppenheimer Outperform $22 → $24
May-07-20Reiterated H.C. Wainwright Buy $37 → $31
Jan-10-20Initiated BofA/Merrill Neutral $27
Jan-09-20Initiated SunTrust Buy $32
Dec-19-19Initiated Citigroup Buy $36
Nov-07-19Reiterated H.C. Wainwright Buy $55 → $41
Oct-30-19Reiterated Needham Buy $54 → $48
Aug-08-19Reiterated Needham Buy $74 → $54
Aug-08-19Reiterated Cantor Fitzgerald Overweight $85 → $62
Mar-21-19Initiated Piper Jaffray Overweight $80
Jul-13-18Reiterated Needham Buy $76 → $86
Feb-16-18Resumed H.C. Wainwright Buy $78
Jan-26-18Initiated Seaport Global Securities Buy $78
Oct-24-17Initiated Guggenheim Buy $80
Oct-16-17Reiterated Needham Buy $65 → $76
Jul-20-17Reiterated Cantor Fitzgerald Overweight $56 → $62
May-25-17Reiterated Needham Buy $58 → $65
Sep-17-21 07:40AM  
Sep-16-21 04:13PM  
Sep-15-21 04:01PM  
Sep-13-21 06:30AM  
Sep-07-21 07:30AM  
Sep-03-21 11:31AM  
Aug-12-21 07:30AM  
Aug-05-21 11:42AM  
Aug-04-21 11:31PM  
Jul-28-21 07:30AM  
Jul-20-21 04:01PM  
Jul-15-21 06:30AM  
Jun-21-21 07:00AM  
Jun-17-21 06:30AM  
Jun-15-21 07:30AM  
Jun-04-21 11:31AM  
May-26-21 06:34PM  
May-06-21 01:24PM  
May-05-21 06:05PM  
May-04-21 09:17AM  
Apr-29-21 06:30AM  
Apr-28-21 12:34PM  
Apr-19-21 06:30AM  
Apr-07-21 07:30AM  
Mar-30-21 08:05AM  
Mar-27-21 11:31AM  
Mar-11-21 07:30AM  
Mar-03-21 05:33PM  
Mar-01-21 10:59AM  
Feb-28-21 04:59AM  
Feb-25-21 05:45PM  
Feb-22-21 07:30AM  
Feb-18-21 07:30AM  
Jan-11-21 06:30AM  
Dec-16-20 11:07PM  
Dec-05-20 11:31AM  
Dec-03-20 11:17PM  
Nov-25-20 10:36AM  
Nov-16-20 10:06AM  
Nov-13-20 06:50AM  
Nov-10-20 07:30AM  
Nov-07-20 01:30AM  
Nov-06-20 10:50AM  
Nov-05-20 06:25PM  
Nov-03-20 09:46AM  
Oct-29-20 12:35PM  
Oct-28-20 03:00AM  
Oct-27-20 07:30AM  
Oct-20-20 06:28AM  
Oct-15-20 09:20AM  
Oct-14-20 12:30AM  
Oct-05-20 12:01PM  
Sep-30-20 09:10AM  
Sep-29-20 06:30AM  
Sep-24-20 06:30AM  
Sep-18-20 09:00AM  
Sep-15-20 06:45AM  
Sep-09-20 07:45AM  
Sep-08-20 07:30AM  
Sep-05-20 11:31AM  
Aug-21-20 09:01AM  
Aug-10-20 10:01AM  
Aug-07-20 10:53AM  
Aug-06-20 04:01PM  
Jul-30-20 07:30AM  
Jul-29-20 12:33PM  
Jul-27-20 06:30AM  
Jul-17-20 02:06PM  
Jul-02-20 08:11AM  
Jun-15-20 06:04PM  
Jun-11-20 06:30AM  
Jun-05-20 11:31AM  
Jun-03-20 03:40AM  
May-11-20 07:15PM  
May-07-20 06:30PM  
May-06-20 05:15PM  
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kopczynski Casey C.Chief Scientific OfficerFeb 15Option Exercise0.2060,65111,888265,522Feb 17 05:40 PM
Kopczynski Casey C.Chief Scientific OfficerNov 11Sale13.0122,695295,210196,114Nov 12 05:03 PM
Kopczynski Casey C.Chief Scientific OfficerNov 10Sale13.007,30594,965218,809Nov 12 05:03 PM